epirubicin has been researched along with Benign Neoplasms in 171 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 35 (20.47) | 18.7374 |
| 1990's | 44 (25.73) | 18.2507 |
| 2000's | 34 (19.88) | 29.6817 |
| 2010's | 47 (27.49) | 24.3611 |
| 2020's | 11 (6.43) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, FP; Butler, WE; Cloonan, S; Devery, A; Draper, SM; Kenny, PT; Moran, BW; Varughese, S | 1 |
| Kharbanda, S; Singh, H; Tiwari, S | 1 |
| Li, Z; Ning, F; Song, T; Sun, Y; Tan, J; Yan, J; Yu, H | 1 |
| Abnous, K; Alibolandi, M; Moradi, E; Ramezani, M; Taghdisi, SM; Zavvar, T | 1 |
| Heibloem, RE; Ilozumba, OUC; Komen, MMC; van den Hurk, CJG | 1 |
| Adebisi, G; Owumi, SE | 1 |
| Amant, FCH; Beijnen, JH; Damoiseaux, D; Dorlo, TPC; Huitema, ADR; Janssen, JM; van Calsteren, K; van Hasselt, JGC | 1 |
| Amant, F; Cinnante, C; Contarino, V; Counsell, S; Fontana, C; Fumagalli, M; Grossi, E; Mosca, F; Ossola, M; Passera, S; Peccatori, F; Pesenti, N; Pisoni, S; Scarfone, G; Scola, E; Triulzi, F | 1 |
| Deng, Y; Ding, J; Hu, Y; Liao, X; Liu, M; Liu, X; Song, Y; Zhao, B; Zhao, D | 1 |
| Cao, J; Du, C; Han, S; Liang, M; Liang, Y; Ma, Q; Qi, J; Song, B; Sun, Q; Sun, Y | 1 |
| Adamkiewicz-Drożynska, E; Bączek, T; Bień, E; Kowalski, P; Krawczyk, MA; Maliszewska, O; Miękus, N; Olędzka, I; Plenis, A; Treder, N | 1 |
| Niazmand, H; Shakiba, A; Sodagar, H | 1 |
| Chen, E; Han, S; Liang, M; Song, B; Sun, Y; Xu, L; Yuan, H | 1 |
| Amant, FCH; Beijnen, JH; Bekkers, R; Boere, I; Dorlo, TPC; Drochytek, V; Fruscio, R; Halaska, MJ; Huitema, ADR; Janssen, JM; Ottevanger, P; Painter, RC; Schröder, CP; Van Calsteren, K; Witteveen, PO | 1 |
| Hepel, M; Herschkowitz, JI; Kurzątkowska, K; Pazos, MA | 1 |
| Deng, Y; Di, D; Hu, L; Liu, X; Liu, Y; Luo, X; Peng, B; Song, Y; Zhang, T; Zhou, S | 1 |
| Boratyński, J; Filip-Psurska, B; Goszczyński, TM; Kmiecik, SW; Krzyścik, MA; Wietrzyk, J | 1 |
| An, Y; Chen, T; Chen, Y; Dong, Y; Fu, L; Jin, B; Jin, F; Jin, X; Liu, J; Liu, Y; Luo, Y; Man, L; Qu, J; Qu, X; Shi, J; Sun, T; Teng, Y; Teng, Z; Wang, J; Wang, Z; Wen, F; Xie, X; Yu, P; Yuan, C; Zhang, J; Zhang, L; Zhang, X; Zhao, M; Zhou, L; Zhu, Z | 1 |
| Farkhani, SM; Golkar, N; Mohammadi, S; Nokhodchi, A; Shahbazi Mojarrad, J; Shirani, A; Valizadeh, H; Zakeri-Milani, P | 1 |
| Brueggemann, O; García-Fernández, A; Hoerhager, C; Matínez-Máñez, R; Resmini, M; Salinas, Y; Sancenón, F | 1 |
| Annibali, O; Armento, G; Calabrese, V; Greco, C; Marchesi, F; Menna, P; Minotti, G; Reggiardo, G; Salvatorelli, E | 1 |
| Arshad, N; Nosheen, B; Nowsherwan, J; Perveen, F; Qureshi, R; Rafique, H; Sultan, A | 1 |
| Abnous, K; Arab, A; Bahreyni, A; Nabavinia, MS; Rafatpanah, H; Ramezani, M; Taghdisi, SM; Yazdian-Robati, R | 1 |
| Cong, Z; Davitt, F; Garcia-Gil, A; Guo, J; Holmes, JD; O'Driscoll, CM; Pei, J; Rahme, K; Sun, T; Wang, L; Zou, Y | 1 |
| Chen, X; Han, W; Tang, W; Wang, F; Zhao, X | 1 |
| Cai, C; Guo, Q; Han, J; Liu, J; Liu, M; Shi, Y; Wu, Y; Zhao, Y | 1 |
| Ju, RJ; Li, N; Li, XY; Lu, WL; Ma, X; Wang, XX; Zhang, CX; Zhang, L; Zhao, WY; Zhou, J | 1 |
| Chen, LJ; Jiang, X; Jin, RR; Li, X; Lin, GY; Lin, M; Lu, CT; Lv, HF; Shen, XT; Su, ZX; Zhang, M; Zhao, YZ | 1 |
| Amant, F; Beijnen, JH; Han, S; Heyns, L; Huitema, ADR; Mhallem Gziri, M; Schellens, JHM; van Calsteren, K; van Hasselt, JGC | 1 |
| Matsumura, Y | 1 |
| Chen, W; Chen, Z; Huang, YZ; Liang, XG; Liu, L; Lou, Y; Lu, XY; Miao, J; Rao, YF; Tang, RK; Wang, B; Zhang, XG | 1 |
| Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y | 1 |
| Cabral, H; Kataoka, K | 1 |
| Berveiller, P; Mir, O; Selleret, L | 1 |
| Amin, M; Hanafi-Bojd, MY; Jaafari, MR; Malaekeh-Nikouei, B; Ramezanian, N; Shahtahmassebi, N; Xue, M | 1 |
| Bartsch, R; Deutschmann, C; Felberbauer, FX; Hacker, S; Haslik, W; Kornauth, C; Mader, RM; Thallinger, C | 1 |
| An, Y; Du, P; He, X; Le Pivert, P; Li, J; Xiao, Y; Zhang, X | 1 |
| Li, G; Liu, F; Yang, Y; Zhang, L; Zhou, Y | 1 |
| Abnous, K; Hanafi-Bojd, MY; Jaafari, MR; Malaekeh-Nikouei, B; Ramezanian, N | 1 |
| Kopeček, J; Wang, J; Yang, J; Zhang, L; Zhang, R | 1 |
| Dieras, V; Evans, TJ; Giordano, H; Goble, S; Jaw-Tsai, S; Middleton, MR; Molife, LR; Plummer, R; Roxburgh, P; Spicer, J; Wilson, RH | 1 |
| Nesterov, VV; Shkolnik, EL; Shkolnik, LD; Varlan, GV; Vasyuk, YA | 1 |
| Berlin, JD; Chan, E; Goff, LW; Lockhart, AC; Roth, BJ; Rothenberg, ML; VerMeulen, WL | 1 |
| Antoni, G; Cadeddu, C; Dessì, M; Madeddu, C; Mantovani, G; Massa, E; Mercuro, G; Piras, A; Serpe, R | 1 |
| de Camargo, B; del Giglio, A; Lajolo, PP | 1 |
| Bicaku, E; Centeno, B; Daud, A; Kim, J; Lacevic, M; Marchion, D; Minton, S; Munster, P; Neuger, A; Sullivan, D | 1 |
| Dreisbach, L; Kristedja, T; Kurtin, S; Mahadevan, D; Obregon, Y; Von Hoff, DD; Williams, D | 1 |
| Friberg, LE; Hansson, EK; Karlsson, MO; Lindman, H; Sandström, M; Wallin, JE | 1 |
| Imasaka, T; Kaneta, T; Mbuna, J | 1 |
| Caron, HN; Kremer, LC; Michiels, EM; van Dalen, EC | 3 |
| Desmedt, C; Dionysiou, DD; Georgiadi, ECh; Kolokotroni, EA; Stamatakos, GS | 1 |
| Bai, YG; Gao, FP; Li, L; Li, RF; Li, XM; Liu, LR; Tang, HB; Wang, YS; Zhang, QQ | 1 |
| Canal, F; Pasut, G; Schiavon, O; Vicent, MJ | 1 |
| Caron, HN; Hauptmann, M; Kok, WE; Koning, CC; Kremer, LC; Oldenburger, F; van Dalen, EC; van den Bos, C; van der Pal, HJ; van Leeuwen, FE | 1 |
| Lü, WL; Mei, XG; Wu, C; Wu, Y; Yang, Y; Zhang, FC | 1 |
| Glimelius, B; Lahn, M | 1 |
| Honda, J; Kamatani, N; Kubo, M; Nakamura, Y; Sasa, M; Srinivasan, Y; Takahashi, A; Uno, S; Zembutsu, H | 1 |
| Reitsma, PH; Van Den Berg, YW | 1 |
| Blackwood, L; Grant, IA; Killick, DR; Marrington, AM | 1 |
| Adoh, A; Adoubi, I; Adoubi, K; Anzouan-Kacou, JB; Didi-Kouko, C; Pio, M; Tegnan, A | 1 |
| AitRaiss, M; Benhmidoun, MA; Derhem, N; Elalouani, C; Elguenzri, A; Elhattaoui, M; Elomrani, A; Errehmouni, A; Faouzi, R; Khouchani, M; Mahmal, L; Rida, H; Tahri, A; Tazi, I | 1 |
| Baldi, A; Citro, G; Fanciulli, M; Spugnini, EP | 1 |
| Aapro, M | 1 |
| Carrió, I; Dalesio, O; Estorch, M; Hoefnagel, CA; López-Pousa, J; ten Bokkel Huinink, WW; Valdés Olmos, RA | 1 |
| Baidas, S; Marshall, JL; Rizvi, N | 1 |
| Ashley, DM; Baum, CM; Caruso, DA; Koina, C; Radcliff, FJ; Riordan, MJ; Roberts, AW; Tang, ML; Woulfe, SL | 1 |
| Colella, E; Falasca, G; Galati, R; Tonachella, R; Verdina, A | 1 |
| Ackland, SP; Clarke, S; Garg, MB; Millward, MJ; Rischin, D; Smith, J; Toner, GC; Zalcberg, J | 1 |
| Davidson, A; Dick, G; Pinkerton, R; Pritchard-Jones, K | 1 |
| Alessandrino, PE; Bertolini, A; Collovà, E; Danova, M; Ferrari, S; Porta, C; Riccardi, A; Rovati, B | 1 |
| Etrych, T; Jelínková, M; Kovár, M; Kubácková, K; Mrkvan, T; Plocová, D; Pokorná, J; Ríhová, B; Rozprimová, L; Sírová, M; Strohalm, J; Ulbrich, K | 1 |
| Hwang, JJ; Marshall, JL; Rizvi, N | 1 |
| Chen, X; Davis, AJ; Kochman, D; Kusenda, Z; Moore, MJ; Oza, AM; Siu, LL; Yi, QL | 1 |
| Bahrs, H; Gruber, Y; Kempgens, B; Kisro, J; Wagner, T | 1 |
| Dobbs, NA; Ralph, LD; Thomson, AH; Twelves, C | 1 |
| Abildgaard, U; Bie, P; Daugaard, G; Hesse, B; Jensen, KT; Kjaer, A; Lassen, U; Pedersen, EB | 1 |
| Cree, IA; Di Nicolantonio, F; Di Palma, S; Fernando, A; Gabriel, FG; Glaysher, S; Gulliford, T; Higgins, B; Hurren, J; Johnson, P; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Somers, SS; Toh, S; Whitehouse, PA; Yiangou, C | 1 |
| Arnold, RD; Ballot, J; Clynes, M; Collins, CD; Crown, J; Fennelly, D; Kennedy, S; Kinsella, P; Larkin, A; Mager, DE; O'Connor, R; O'Driscoll, L; O'Leary, M | 1 |
| Bonneterre, J; Chollet, P; Clavère, P; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Monnier, A; Roché, H; Serin, D | 1 |
| Basar, E; Cetinkaya, Y; Dogan, A; Er, O; Ergin, A; Eryol, NK; Inanc, T; Kalay, N; Oguzhan, A; Ozdogru, I; Topsakal, R | 1 |
| Carraway, HE; Gore, SD | 1 |
| Bicaku, E; Chiappori, A; Daud, A; DeConti, R; Fishman, M; Garrett, C; Lee, JH; Lush, R; Marchion, D; Minton, S; Münster, P; Schmitt, M; Simon, G; Sullivan, D | 1 |
| Bremberg, ER; Eksborg, S; Rotstein, S | 1 |
| Ceccobelli, D; Distrutti, E; Fiorucci, S; Mencarelli, A; Pasut, G; Renga, B; Santucci, L; Veronese, FM | 1 |
| Marik, PE; Vahid, B | 1 |
| Ogawa, M | 2 |
| Beretta, L; Italia, C; Luchini, S; Marelli, G; Natale, N; Paglia, L; Trabattoni, A; Villas, F | 1 |
| Armand, JP; Cappelaere, P; Hurteloup, P; Mathé, G | 1 |
| Cervek, J; Kolarić, K; Potrebica, V | 1 |
| Farabegoli, G; Ganzina, F; Giovannini, M; Martoni, A; Monetti, N; Pannuti, F; Tomasi, L | 1 |
| Bellanova, B; Camaggi, CM; Giovannini, M; Martini, A; Martoni, A; Monetti, N; Pannuti, F; Rossini, G; Tarquinii, M; Tomasi, L | 1 |
| Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Nakada, K; Ogawa, M; Okada, Y; Tada, A; Usui, N | 1 |
| Ganzina, F; Pavesi, L; Preti, P; Robustelli Della Cuna, G | 1 |
| Kohsaki, G; Mori, T | 1 |
| Martini, A; Moro, E; Natale, N; Pacciarini, MA; Piazza, E; Tamassia, V | 1 |
| Fujimoto, T; Kimura, K; Masaoka, T; Niitani, H; Saito, T; Tamura, K; Toki, H; Tominaga, T; Wakui, A | 1 |
| Bonadonna, G; Bonfante, V; Martini, A; Villani, F | 1 |
| Bonadonna, G; Bonfante, V; Villani, F | 1 |
| Camaggi, CM; Canova, N; Giovannini, M; Lafelice, G; Marraro, D; Martini, A; Martoni, A; Pannuti, F; Strocchi, E; Tamassia, V | 1 |
| Ferrazzi, E; Fiorentino, MV; Ganzina, F; Maraglino, G; Nicoletto, O; Pagnin, P; Vinante, O | 1 |
| Berenson, RJ; Brugger, W; Heimfeld, S; Henschler, R; Kanz, L; Mertelsmann, R | 1 |
| Dercksen, MW; Dirkson, MK; Gerritsen, WR; Pinedo, HM; Rodenhuis, S; Schaasberg, WP; Slaper-Cortenbach, IC; van der Schoot, CE; von dem Borne, AE | 1 |
| Bettelheim, P; Kasparu, H; Kolb, A; Krieger, O; Lutz, D | 1 |
| Faulds, D; Plosker, GL | 1 |
| Bruning, PF; Hoefnagel, CA; ten Bokkel Huinink, WW; ten Hoeve, RF; Valdés Olmos, RA; van Tinteren, H; van Vlies, B | 1 |
| Bandak, S; Czejka, M; Schernhammer, E; Schüller, J | 1 |
| Robert, J | 2 |
| Cosolo, WC; McKendrick, JJ; Morgan, DJ; Seeman, E; Zalcberg, JR; Zimet, AS | 1 |
| Basser, RL; Cebon, J; Duggan, G; Green, MD; Mihaly, G; Rosenthal, MA; Sobol, MM | 1 |
| Habboubi, N; Launchbury, AP | 1 |
| Bidoli, P; Bonadonna, G; Bonfante, V; Casali, P; Demicheli, R; Gianni, L; Santoro, A; Valagussa, P | 1 |
| Jantunen, IT; Kataja, VV; Muhonen, TT; Parviainen, T | 1 |
| Berdel, WE; Bron, DG; Cunningham, D; de Campos, E; De Greve, J; Howell, A; Seymour, AM; Steward, WP; Thatcher, N; Tueni, E | 1 |
| Berchem, GJ; Delagardelle, C; Dicato, M; Duhem, C; Hanfelt, J; Keipes, M; Ries, F | 1 |
| Bergemann, C; Dörken, B; Gürtler, R; Haas, N; Herrmann, F; Hohenberger, P; Huhn, D; Huhnt, W; Lemke, AJ; Lübbe, AS; Matthias, M; Ohlendorf, D; Possinger, K; Reichardt, P; Riess, H; Sander, B; Schriever, F; Sohr, R | 1 |
| Bergemann, C; Brock, JW; Fricke, T; Huhn, D; Huhnt, W; Lübbe, AS; Riess, H | 1 |
| Gaarsdal, E; Jensen, L; Johnsen, HE; Knudsen, LM; Nielsen, KJ; Nikolaisen, K | 1 |
| Kastner, J; Kornek, G; Raderer, M; Weinländer, G | 1 |
| Bishop, JF; Fenessy, A; Michael, M; Olver, IN; Toner, GC | 1 |
| Bessho, A; Harada, M; Higuchi, M; Miyamoto, T; Miyoshi, T; Ohno, Y; Omoto, E; Shinagawa, K; Sunami, K; Teshima, T; Ueoka, H | 1 |
| Gallo, JM; Hafeli, U | 1 |
| Bialkowski, K; Foksinski, M; Jaruga, P; Olinski, R; Tujakowski, J | 1 |
| Cripps, MC; Dahrouge, S; Davies, RA; Goel, R; Huan, S; Prosser, A; Soltys, K; Stewart, DJ; Tomiak, E; Yau, J | 1 |
| Eggert, J; Eising, EG; Gries, P; Scheulen, ME | 1 |
| Blumenstengel, K; Fricke, HJ; Höffken, K; Kath, R; Kunert, C; Sayer, HG; Vogel, W | 1 |
| Bramwell, V; Moran, LA; Seymour, L | 1 |
| Caramatti, C; Cesana, C; Garau, D; Mangoni, L; Regazzi, E; Rizzoli, V | 1 |
| Bishop, J; Fox, RM; Green, MD; Grigg, AP; Levi, J; McKendrick, J; Talbot, SM; Toner, GC; Westerman, DA; Wolf, M; Zalcberg, J | 1 |
| Bishop, JF; Francis, P; Ganju, V; Millward, MJ; Nawaratne, S; Rischin, D; Toner, GC; Webster, LK | 1 |
| Bergh, J; Csoka, K; Larsson, R; Nygren, P; Sandström, M; Tholander, B; von Heideman, A | 1 |
| Boccardo, F; Foglia, G; Marenghi, C; Miglietta, L; Nizzo, R; Ragni, N | 1 |
| Herman, ZS; Machalski, M; Scieszka, M; Zielinski, M | 1 |
| Beijnen, JH; Hoekman, K; Huijskes, RV; Nannan Panday, VR; Rosing, H; Van den Brande, J; Verheijen, RH; Vermorken, JB | 1 |
| Conte, P; Danesi, R; Del Tacca, M; Fogli, S; Gennari, A | 1 |
| Narasimha, K | 1 |
| Brown, TD; Burris, HA; Havlin, KA; O'Rourke, TJ; Rodriguez, GI; Wall, JG; Weiss, GR | 1 |
| Yamada, S | 1 |
| Hausamen, TU; Loeffler, TM; Weber, FW | 1 |
| de Vries, EG; Hoekstra, HJ; Mulder, NH; Nanninga, AG; Oosterhuis, BE; Sleijfer, DT; Willemse, PH | 1 |
| Green, MD; Muggia, FM | 1 |
| Kotasek, D; Morris, RG; Paltridge, G | 1 |
| Abbasciano, V; Maestri, A; Nielsen, I; Sartori, S; Tassinari, D | 1 |
| Guaraldi, M; Martoni, A; Melotti, B; Pacciarini, MA; Pannuti, F; Riva, A | 1 |
| Alfthan, C; Bastholt, L; Bergh, J; Dalmark, M; Eksborg, S; Hellsten, S; Kjaer, M; Mouridsen, HT; Peterson, C; Skovsgård, T | 1 |
| David, M; Granger, C; Robert, J | 1 |
| Doig, RG; Green, MD; Mihaly, G; Morstyn, G; Sheridan, WP; Sobol, MM; Tjuljandin, SA; Watson, DM | 1 |
| Tsukagoshi, S | 1 |
| Guedes, Y; Kernaleguen, D; Labat, JP; Le Bot, MA; Riche, C; Robert, J; Swirsky, H | 1 |
| Beuzeboc, P; Dorval, T; Garcia-Giralt, E; Jouve, M; Palangie, T; Pouillart, P; School, S | 1 |
| Bandinelli, M; Bartalucci, S; Ciapini, A; Cini-Neri, G; Neri, B; Pacini, P | 1 |
| Barni, S; Crispino, S; Esposti, D; Esposti, G; Ferri, L; Fumagalli, G; Lissoni, P; Paolorossi, F; Rovelli, F; Tancini, G | 1 |
| Camaggi, CM; Pannuti, F; Strocchi, E | 1 |
| Cersosimo, RJ; Hong, WK | 1 |
| De Langen, ZJ; De Vries, EG; Greidanus, J; Oremus, ET; Uges, DR; Willemse, PH | 1 |
| Angelelli, B; Camaggi, CM; Comparsi, R; Pannuti, F; Strocchi, E; Testoni, F | 2 |
| Ariyoshi, Y; Okuma, K; Ota, K | 1 |
| Maciejewicz, J; Pawlicki, M; Zuchowska-Vogelgesang, B | 1 |
| Kimura, K; Ohno, T; Shimoyama, T; Yamada, H | 1 |
| Kojder, R; Maciejewicz, J; Pawlicki, M; Zuchowska-Vogelgesang, B | 1 |
| de Vries, EG; Greidanus, J; Mulder, NH; Nieweg, MB; Postmus, PE; Schipper, DL; Sleijfer, DT; Uges, DR; Willemse, PH | 1 |
| de Langen, ZJ; de Vries, EG; Greidanus, J; Nieweg, MB; Willemse, PH | 1 |
| Ganzina, F; Hurteloup, P | 1 |
| Mechl, Z | 1 |
| Falkson, G; Iturralde, M; Vorobiof, DA | 1 |
| Angelelli, B; Camaggi, CM; Comparsi, R; Martoni, A; Pannuti, F; Strocchi, E | 1 |
25 review(s) available for epirubicin and Benign Neoplasms
| Article | Year |
|---|---|
The drug discovery by nanomedicine and its clinical experience.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Cisplatin; Clinical Trials, Phase I as Topic; Drug Delivery Systems; Drug Discovery; Epirubicin; Gas Chromatography-Mass Spectrometry; Humans; Mass Spectrometry; Micelles; Nanomedicine; Nanoparticles; Neoplasms; Neoplasms, Experimental; Organoplatinum Compounds; Paclitaxel; Polyethylene Glycols; Polyglutamic Acid; Proteins | 2014 |
Progress of drug-loaded polymeric micelles into clinical studies.
Topics: Antineoplastic Agents; Camptothecin; Delayed-Action Preparations; Drug Carriers; Epirubicin; Humans; Irinotecan; Micelles; Neoplasms; Paclitaxel; Platinum Compounds; Polymers | 2014 |
[Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].
Topics: Aclarubicin; Anthracyclines; Antibiotics, Antineoplastic; Cardiotoxicity; Doxorubicin; Epirubicin; Humans; Neoplasms | 2016 |
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
Topics: Adult; Antibiotics, Antineoplastic; Cardiac Output, Low; Child; Doxorubicin; Epirubicin; Heart; Humans; Liposomes; Neoplasms; Randomized Controlled Trials as Topic | 2010 |
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
Topics: Adult; Antibiotics, Antineoplastic; Cardiac Output, Low; Child; Doxorubicin; Epirubicin; Heart; Humans; Liposomes; Neoplasms; Randomized Controlled Trials as Topic | 2010 |
Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology.
Topics: Adult; Antineoplastic Agents; Child; Clinical Trials as Topic; Epirubicin; Etoposide; Humans; Melphalan; Molecular Targeted Therapy; Neoplasms; Topotecan | 2011 |
Preclinical models in electrochemotherapy: the role of veterinary patients.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cat Diseases; Cats; Cisplatin; Dog Diseases; Dogs; Drug Evaluation, Preclinical; Electrochemotherapy; Epirubicin; Head and Neck Neoplasms; Melanoma; Mitoxantrone; Neoplasms; Quinazolines; Sarcoma; Thiophenes | 2012 |
Drug-HPMA-HuIg conjugates effective against human solid cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Heart Neoplasms; Heart Transplantation; Hemangiosarcoma; Hempa; Humans; Immunoglobulin G; Immunotherapy; Lymphatic Metastasis; Middle Aged; Neoplasms | 2003 |
Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Evaluation; Drug Therapy, Combination; Enzyme Inhibitors; Epirubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase Inhibitors | 2003 |
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
Topics: Adult; Antibiotics, Antineoplastic; Cardiac Output, Low; Child; Doxorubicin; Epirubicin; Heart; Humans; Liposomes; Neoplasms; Randomized Controlled Trials as Topic | 2006 |
Pulmonary complications of novel antineoplastic agents for solid tumors.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Everolimus; Gemcitabine; Humans; Lung; Lung Diseases; Mitoxantrone; Neoplasms; Pneumonia; Pyrimidines; Risk Factors; Sirolimus; Teniposide; Trastuzumab | 2008 |
Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
Topics: Clinical Trials as Topic; Epirubicin; Female; Humans; Male; Neoplasms | 1993 |
[Pharmacokinetic mechanisms of resistance to anticancer medications].
Topics: Antineoplastic Agents; Blood-Brain Barrier; Dose-Response Relationship, Drug; Drug Resistance; Epirubicin; Fluorouracil; Humans; Neoplasms | 1994 |
Clinical pharmacokinetics of epirubicin.
Topics: Aging; Animals; Drug Interactions; Epirubicin; Half-Life; Humans; Metabolic Clearance Rate; Neoplasms; Structure-Activity Relationship; Tissue Distribution; Tumor Cells, Cultured | 1994 |
Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Humans; Neoplasms | 1993 |
Drugs ten years later: epirubicin.
Topics: Cardiomyopathies; Epirubicin; Female; Humans; Male; Neoplasms | 1993 |
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Area Under Curve; Doxorubicin; Epirubicin; Half-Life; Humans; Idarubicin; Metabolic Clearance Rate; Neoplasms; Prodrugs; Structure-Activity Relationship | 2002 |
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine; Echinomycin; Epirubicin; Etanidazole; Flavonoids; Gemcitabine; Guanidines; Humans; Idarubicin; Menogaril; Mitoguazone; Neoplasms; Nitroimidazoles; Nogalamycin; Organoplatinum Compounds; Paclitaxel; Pentostatin; Polymers; Propylene Glycols; Ribavirin; Sulfonylurea Compounds; Trimetrexate; Vidarabine Phosphate | 1991 |
New anthracycline antitumor antibiotics.
Topics: Aclarubicin; Antibiotics, Antineoplastic; Cardiomyopathies; Carubicin; Doxorubicin; Drug Resistance; Epirubicin; Humans; Idarubicin; Menogaril; Molecular Structure; Neoplasms; Nogalamycin | 1991 |
Current status of epirubicin (Farmorubicin) in the treatment of solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Epirubicin; Humans; Neoplasms | 1990 |
[Epirubicin (4'-epi-adriamycin].
Topics: Animals; Doxorubicin; Epirubicin; Humans; Neoplasms; Neoplasms, Experimental | 1990 |
Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.
Topics: Bone Marrow; Breast Neoplasms; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Head and Neck Neoplasms; Heart; Humans; Kidney Neoplasms; Kinetics; Leukemia; Liver Neoplasms; Lung Neoplasms; Lymphoma; Male; Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Soft Tissue Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms | 1986 |
Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: a review.
Topics: Doxorubicin; Epirubicin; Humans; Infusions, Intravenous; Mitoxantrone; Neoplasms | 1988 |
Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
Topics: Antibiotics, Antineoplastic; Bone Marrow; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Drug Evaluation; Epirubicin; Heart; Humans; Idarubicin; Neoplasms | 1986 |
[Current status of clinical results of new antitumor drugs].
Topics: Aminoacridines; Amsacrine; Anthracyclines; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents; Aziridines; Benzoquinones; Carboplatin; Carubicin; Cisplatin; Daunorubicin; Doxorubicin; Eflornithine; Epirubicin; Humans; Idarubicin; Mitoxantrone; Naphthacenes; Neoplasms; Organoplatinum Compounds; Ornithine; Ribavirin | 1985 |
38 trial(s) available for epirubicin and Benign Neoplasms
| Article | Year |
|---|---|
Minimal added value of wetting hair before scalp cooling to prevent chemotherapy-induced alopecia in cancer patients - results from the Dutch Scalp Cooling Registry.
Topics: Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Hair; Humans; Hypothermia, Induced; Neoplasms; Paclitaxel; Registries; Scalp | 2023 |
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Epirubicin; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Thalidomide; Vomiting; Young Adult | 2017 |
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Doxorubicin; Electric Stimulation Therapy; Epirubicin; Humans; Ifosfamide; Isoquinolines; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting; Young Adult | 2014 |
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Prognosis; Survival Rate; Tissue Distribution | 2017 |
A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Epirubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost Savings; Dexamethasone; Double-Blind Method; Doxorubicin; Epirubicin; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Prognosis; Prospective Studies; Ranitidine; Treatment Outcome; Vomiting | 2009 |
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Cyclophosphamide; Enzyme Inhibitors; Epirubicin; Female; Fluorouracil; Histone Deacetylase Inhibitors; Histones; Humans; Leukocytes; Male; Middle Aged; Neoplasms; Valproic Acid | 2009 |
Phase I study of fixed dose gemcitabine plus epirubicin in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2009 |
High sensitivity of radiolabelled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Doxorubicin; Epirubicin; Follow-Up Studies; Heart; Humans; Indium Radioisotopes; Middle Aged; Myocardium; Myocytes, Cardiac; Myosins; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Stroke Volume; Ventricular Dysfunction, Left | 2002 |
Phase I trial of irinotecan and epirubicin in advanced cancer. Preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasm Staging; Neoplasms; Patient Selection; Prognosis; Survival Rate; Treatment Outcome | 2002 |
Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Confidence Intervals; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Probability; Risk Assessment; Sensitivity and Specificity; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Evaluation; Drug Therapy, Combination; Enzyme Inhibitors; Epirubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase Inhibitors | 2003 |
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Epirubicin; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2003 |
Two schedules of application for mesna and their influence on the thiol-metabolism.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Etoposide; Humans; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; Mesna; Neoplasms; Protective Agents; Sulfhydryl Compounds | 2003 |
A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chemotherapy, Adjuvant; Creatinine; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Immunohistochemistry; Male; Middle Aged; Myocardium; Neoplasms; Platelet Count; Prospective Studies; Sulindac; Troponin | 2007 |
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Estrogen Antagonists; Female; Fluorouracil; Gonadotropin-Releasing Hormone; Heart Diseases; Humans; Lymph Node Excision; Middle Aged; Neoplasms; Premenopause; Receptors, Steroid; Tamoxifen; Triptorelin Pamoate | 2006 |
Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Anthracyclines; Antibiotics, Antineoplastic; Blood Flow Velocity; Carbazoles; Cardiomyopathies; Carvedilol; Coronary Circulation; Diastole; Doxorubicin; Echocardiography, Doppler; Epirubicin; Female; Follow-Up Studies; Heart Ventricles; Humans; Male; Middle Aged; Neoplasms; Propanolamines; Single-Blind Method; Stroke Volume; Systole; Ventricular Function, Left | 2006 |
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Drug Therapy, Combination; Enzyme Inhibitors; Epirubicin; Female; Histone Deacetylase Inhibitors; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Survival Rate; Topoisomerase II Inhibitors; Treatment Outcome; Valproic Acid | 2007 |
Treatment modifications of antineoplastic drugs in an oncology day-care unit.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Interactions; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Sweden; Treatment Outcome | 2007 |
Cross-over study of pharmacokinetics and haematological toxicity of 4'-epi-doxorubicin and doxorubicin in cancer patients.
Topics: Aged; Doxorubicin; Epirubicin; Female; Hematologic Diseases; Humans; Injections, Intravenous; Kinetics; Male; Middle Aged; Models, Biological; Neoplasms | 1984 |
Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bleomycin; Blood Transfusion, Autologous; Breast Neoplasms; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Epirubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasms; Predictive Value of Tests; Vincristine | 1994 |
Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells.
Topics: Adult; Aged; Cross-Over Studies; Drug Interactions; Epirubicin; Erythrocytes; Female; Half-Life; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Neoplasms; Protein Binding; Recombinant Proteins | 1995 |
Lean body mass, body surface area and epirubicin kinetics.
Topics: Body Mass Index; Body Surface Area; Body Weight; Epirubicin; Humans; Neoplasms; Spectrophotometry, Atomic | 1994 |
Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.
Topics: Adult; Aged; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasms; Razoxane; Stomatitis; Vomiting | 1994 |
Effects of granisetron with doxorubicin or epirubicin on ECG intervals.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antiemetics; Doxorubicin; Drug Interactions; Electrocardiography; Epirubicin; Female; Granisetron; Heart Rate; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Serotonin Antagonists | 1996 |
A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Combination; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Leukocyte Count; Lymphoma; Male; Middle Aged; Neoplasms; Neutropenia; Recombinant Proteins; Single-Blind Method | 1995 |
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Drug Delivery Systems; Epirubicin; Female; Ferritins; Humans; Iron; Magnetics; Male; Middle Aged; Neoplasms | 1996 |
Phase I dose intensification study of 2-weekly epirubicin with GM-CSF in advanced cancer.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Female; Fever; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Prospective Studies | 1997 |
A.S. Lübbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced s
Topics: Antibiotics, Antineoplastic; Epirubicin; Humans; Magnetics; Neoplasms | 1997 |
Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? The Italian Group for Antiemetic Research.
Topics: Acute Disease; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Drug Therapy, Combination; Epirubicin; Female; Granisetron; Humans; Male; Middle Aged; Neoplasms; Prognosis; Time Factors; Vomiting | 1997 |
Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carmustine; Cell Separation; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Epirubicin; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Ifosfamide; Macrophages; Male; Melphalan; Neoplasms; Prednisolone; Vincristine | 1998 |
Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Australia; Cohort Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Recombinant Proteins; Survival Rate; Treatment Outcome | 1999 |
A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Random Allocation | 1999 |
Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2001 |
New anthracycline antitumor antibiotics.
Topics: Aclarubicin; Antibiotics, Antineoplastic; Cardiomyopathies; Carubicin; Doxorubicin; Drug Resistance; Epirubicin; Humans; Idarubicin; Menogaril; Molecular Structure; Neoplasms; Nogalamycin | 1991 |
Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspects.
Topics: Animals; Creatine Kinase; Doxorubicin; Echocardiography; Epirubicin; Female; Heart; Heart Diseases; Humans; Isoenzymes; Male; Middle Aged; Myocardium; Neoplasms; Oxygen Consumption; Rats; Rats, Inbred Strains | 1989 |
[Clinical trial of epirubicin in patients with cardiologic contraindications for the use of doxorubicin].
Topics: Adult; Aged; Cardiovascular Diseases; Clinical Trials as Topic; Doxorubicin; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasms | 1987 |
Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
Topics: Antibiotics, Antineoplastic; Bone Marrow; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Drug Evaluation; Epirubicin; Heart; Humans; Idarubicin; Neoplasms | 1986 |
111 other study(ies) available for epirubicin and Benign Neoplasms
| Article | Year |
|---|---|
Synthesis, structural characterisation and biological evaluation of fluorinated analogues of resveratrol.
Topics: Antibiotics, Antineoplastic; Anticarcinogenic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Epirubicin; Halogenation; Humans; Molecular Structure; Neoplasms; Resveratrol; Stilbenes; Structure-Activity Relationship | 2009 |
Quatramer™ mediated co-delivery of PI3-Kδ/HDAC6 dual inhibitor augments the anti-cancer efficacy of Epirubicin in breast cancer.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Epirubicin; Histone Deacetylase Inhibitors; Mice; Nanoparticles; Neoplasms; Phosphatidylinositol 3-Kinases; Poloxamer; Polymers; Proto-Oncogene Proteins c-akt | 2022 |
Enhanced photothermal-ferroptosis effects based on RBCm-coated PDA nanoparticles for effective cancer therapy.
Topics: Apoptosis; Epirubicin; Ferroptosis; Hydrogen Peroxide; Iron; Nanoparticles; Neoplasms | 2023 |
Targeted delivery of epirubicin to breast cancer cells using poly-aptamer DNA nanocarriers prepared by the RCA method with multiple repeats of aptamers of FOXM1 and AS1411.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; DNA; Drug Delivery Systems; Epirubicin; Mice; Nanoparticles; Neoplasms | 2023 |
Epirubicin Treatment Induces Neurobehavioral, Oxido-Inflammatory and Neurohistology Alterations in Rats: Protective Effect of the Endogenous Metabolite of Tryptophan - 3-Indolepropionic Acid.
Topics: Animals; Antioxidants; Epirubicin; Female; Neoplasms; Oxidative Stress; Rats; Rats, Wistar; Reactive Oxygen Species; Tryptophan | 2023 |
Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs.
Topics: Antineoplastic Agents; Child; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Models, Biological; Neoplasms; Paclitaxel; Pregnancy | 2023 |
Effects of in-utero exposure to chemotherapy on fetal brain growth.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Case-Control Studies; Cohort Studies; Cyclophosphamide; Epirubicin; Female; Fetal Development; Humans; Infant, Newborn; Magnetic Resonance Imaging; Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Exposure Delayed Effects | 2019 |
Terminating the renewal of tumor-associated macrophages: A sialic acid-based targeted delivery strategy for cancer immunotherapy.
Topics: Amines; Animals; Cell Differentiation; Cell Line, Tumor; Disease Models, Animal; Drug Liberation; Epirubicin; Feasibility Studies; Humans; Immunotherapy; Liposomes; Macrophages; Male; Mice; Monocytes; N-Acetylneuraminic Acid; Nanoconjugates; Neoplasms; Rats; RAW 264.7 Cells; Sialic Acid Binding Immunoglobulin-like Lectins; Tissue Distribution; Tumor Microenvironment | 2019 |
Intracellular tracking of drug release from pH-sensitive polymeric nanoparticles via FRET for synergistic chemo-photodynamic therapy.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Delayed-Action Preparations; Drug Liberation; Epirubicin; Fluorescence Resonance Energy Transfer; Humans; Hydrogen-Ion Concentration; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Photosensitizing Agents; Polymers | 2019 |
Development and validation of a high-performance liquid chromatographic method with a fluorescence detector for the analysis of epirubicin in human urine and plasma, and its application in drug monitoring.
Topics: Adult; Antibiotics, Antineoplastic; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Epirubicin; Humans; Limit of Detection; Linear Models; Male; Neoplasms; Reproducibility of Results; Solid Phase Extraction; Spectrometry, Fluorescence; Young Adult | 2020 |
Numerical investigation of drug delivery by using magnetic field in a 90-degree bent vessel: a 3D simulation.
Topics: Atherosclerosis; Biophysics; Blood Vessels; Chemistry, Pharmaceutical; Computer Simulation; Drug Delivery Systems; Epirubicin; Humans; Imaging, Three-Dimensional; Magnetic Fields; Magnetics; Neoplasms; Oscillometry; Particle Size | 2020 |
Mechanism Investigation of Hyaluronidase-Combined Multistage Nanoparticles for Solid Tumor Penetration and Antitumor Effect.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Drug Carriers; Endocytosis; Epirubicin; Humans; Hyaluronoglucosaminidase; Ki-67 Antigen; Male; Mice, Nude; Nanoparticles; Neoplasms; Polymers; Spheroids, Cellular; Tumor Burden; Tumor Microenvironment | 2020 |
Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Infertility; Neoplasms; Paclitaxel; Pregnancy; Pregnant Women; Taxoids | 2021 |
Cancer-Targeted Controlled Delivery of Chemotherapeutic Anthracycline Derivatives Using Apoferritin Nanocage Carriers.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Apoferritins; Cell Line, Tumor; Daunorubicin; Delayed-Action Preparations; Doxorubicin; Drug Delivery Systems; Epirubicin; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; Nanostructures; Neoplasms | 2021 |
Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Survival; Cholesterol; Drug Liberation; Drug Stability; Epirubicin; Liposomes; Macrophages; Male; Mice; Myocardium; N-Acetylneuraminic Acid; Neoplasms; Rats, Wistar; RAW 264.7 Cells; Spleen; Thymus Gland; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
Methotrexate and epirubicin conjugates as potential antitumor drugs.
Topics: Antineoplastic Agents; Drug Design; Epirubicin; Humans; Mass Spectrometry; Methotrexate; Neoplasms | 2017 |
Synthesis and cellular characterization of various nano-assemblies of cell penetrating peptide-epirubicin-polyglutamate conjugates for the enhancement of antitumor activity.
Topics: Antineoplastic Agents; Cell-Penetrating Peptides; Epirubicin; Humans; MCF-7 Cells; Nanoconjugates; Neoplasms; Polyglutamic Acid | 2018 |
Biocompatible Phenylboronic-Acid-Capped ZnS Nanocrystals Designed As Caps in Mesoporous Silica Hybrid Materials for on-Demand pH-Triggered Release In Cancer Cells.
Topics: Biocompatible Materials; Boronic Acids; Delayed-Action Preparations; Epirubicin; HeLa Cells; Humans; Hydrogen-Ion Concentration; Nanoparticles; Neoplasms; Porosity; Silicon Dioxide; Sulfides; Zinc Compounds | 2018 |
The Endogenous Lusitropic and Chronotropic Agent, B-Type Natriuretic Peptide, Limits Cardiac Troponin Release in Cancer Patients with an Early Impairment of Myocardial Relaxation Induced by Anthracyclines.
Topics: Adult; Anthracyclines; Biomarkers; Doxorubicin; Epirubicin; Female; Heart; Humans; Male; Middle Aged; Myocardium; Natriuretic Peptide, Brain; Necrosis; Neoplasms; Pilot Projects; Troponin I | 2018 |
Electrochemical, spectroscopic and theoretical monitoring of anthracyclines' interactions with DNA and ascorbic acid by adopting two routes: Cancer cell line studies.
Topics: Antibiotics, Antineoplastic; Antioxidants; Ascorbic Acid; Cardiotoxicity; Cell Line, Tumor; Cell Proliferation; Daunorubicin; DNA; Doxorubicin; Drug Interactions; Epirubicin; Humans; Hydrogen-Ion Concentration; Molecular Docking Simulation; Neoplasms | 2018 |
Smart aptamer-modified calcium carbonate nanoparticles for controlled release and targeted delivery of epirubicin and melittin into cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aptamers, Peptide; Calcium Carbonate; Cell Line, Tumor; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Drug Screening Assays, Antitumor; Drug Synergism; Epirubicin; Female; Humans; Melitten; Mice; Mice, Inbred BALB C; Mucin-1; Nanoparticles; Neoplasms; Treatment Outcome | 2019 |
Development of anisamide-targeted PEGylated gold nanorods to deliver epirubicin for chemo-photothermal therapy in tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Benzamides; Caspases; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Endocytosis; Epirubicin; Gold; Humans; Hyperthermia, Induced; Intracellular Space; Male; Mice, Inbred BALB C; Mice, Nude; Nanotubes; Neoplasms; Phototherapy; Polyethylene Glycols; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Epirubicin-loaded marine carrageenan oligosaccharide capped gold nanoparticle system for pH-triggered anticancer drug release.
Topics: Antibiotics, Antineoplastic; Carrageenan; Drug Carriers; Drug Delivery Systems; Drug Liberation; Epirubicin; Geologic Sediments; Gold; HCT116 Cells; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Metal Nanoparticles; Neoplasms; Oligosaccharides | 2019 |
Spectroscopic and cytotoxicity studies on the combined interaction of (-)-epigallocatechin-3-gallate and anthracycline drugs with human serum albumin.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Catechin; Cell Survival; Circular Dichroism; Doxorubicin; Entropy; Epirubicin; HeLa Cells; Humans; Neoplasms; Protein Binding; Serum Albumin, Human; Spectrometry, Fluorescence | 2019 |
Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Caspases; Cell Death; Cell Line, Tumor; Cell Survival; Cytochromes c; Drug Delivery Systems; Drug Resistance, Neoplasm; Enzyme Activation; Epirubicin; Female; Humans; Indazoles; Liposomes; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Construction and application of biotin-poloxamer conjugate micelles for chemotherapeutics.
Topics: Animals; Antibiotics, Antineoplastic; Biotin; Drug Carriers; Epirubicin; HL-60 Cells; Humans; Male; Mice; Mice, Nude; Micelles; Neoplasms; Poloxamer | 2013 |
Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.
Topics: Adult; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Humans; Neoplasms; Paclitaxel; Pregnancy; Taxoids | 2014 |
Epirubicin-loaded superparamagnetic iron-oxide nanoparticles for transdermal delivery: cancer therapy by circumventing the skin barrier.
Topics: Antibiotics, Antineoplastic; Biocompatible Materials; Cell Line, Tumor; Drug Delivery Systems; Epirubicin; Ferric Compounds; Humans; Hydrogen-Ion Concentration; Metal Nanoparticles; Neoplasms; Skin; Tumor Microenvironment | 2015 |
Drug selection and dosing in pregnant cancer patients: insights from clinical pharmacokinetics.
Topics: Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoplasms; Paclitaxel; Pregnancy; Taxoids | 2014 |
Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.
Topics: Animals; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Epirubicin; Female; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Particle Size; Polyethylene Glycols; Polyethyleneimine; Porosity; Silicon Dioxide; Tissue Distribution | 2015 |
Port-a-Cath extravasation of vesicant cytotoxics: surgical options for a rare complication of cancer chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Body Mass Index; Cisplatin; Device Removal; Dioxoles; Epirubicin; Equipment Failure; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Risk Factors; Surgical Flaps; Tetrahydroisoquinolines; Therapeutic Irrigation; Trabectedin; Vascular Access Devices; Young Adult | 2015 |
Percutaneous Tumor Ablation: Cryoablation Facilitates Targeting of Free Epirubicin-Ethanol-Ioversol Solution Interstitially Coinjected in a Rabbit VX2 Tumor Model.
Topics: Animals; Antibiotics, Antineoplastic; Cryosurgery; Disease Models, Animal; Drug Compounding; Epirubicin; Ethanol; Injections, Intralesional; Neoplasms; Rabbits; Solutions; Tomography, X-Ray Computed; Triiodobenzoic Acids | 2016 |
Twin-Arginine Translocation Peptide Conjugated Epirubicin-Loaded Nanoparticles for Enhanced Tumor Penetrating and Targeting.
Topics: Animals; Arginine; Cell Line, Tumor; Cell-Penetrating Peptides; Drug Carriers; Drug Delivery Systems; Epirubicin; Humans; Mice; Nanoparticles; Neoplasms; Rats; Tissue Distribution; Twin-Arginine-Translocation System | 2015 |
Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Epirubicin; Female; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Polyethylene Glycols; Polyethyleneimine; Porosity; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Silicon Dioxide; Tumor Burden | 2016 |
Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: Impact of structure on the in vivo fate.
Topics: Acrylamides; Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Epirubicin; Female; Humans; Indium Radioisotopes; Iodine Radioisotopes; Mice, Nude; Neoplasms; Staining and Labeling | 2016 |
Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Biomarkers; Echocardiography, Doppler; Electrocardiography; Epirubicin; Female; Follow-Up Studies; Humans; Interleukin-6; Male; Middle Aged; Neoplasms; Oxidative Stress; Stroke Volume; Time Factors; Ventricular Function, Left | 2008 |
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Count; Cell Enlargement; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Fluorouracil; Humans; Models, Biological; Myelopoiesis; Neoplasms; Neutrophils; Observation; Paclitaxel; Precision Medicine; Taxoids; Topotecan | 2010 |
Measurement of intracellular accumulation of anthracyclines in cancerous cells by direct injection of cell lysate in MEKC/LIF detection.
Topics: Cell Line, Tumor; Chromatography, Micellar Electrokinetic Capillary; Culture Media; Doxorubicin; Epirubicin; Humans; Hydrogen-Ion Concentration; Intracellular Space; Linear Models; Neoplasms; Reproducibility of Results; Spectrometry, Fluorescence | 2010 |
An advanced discrete state-discrete event multiscale simulation model of the response of a solid tumor to chemotherapy: Mimicking a clinical study.
Topics: Algorithms; Antigens, Neoplasm; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Proliferation; Clinical Trials as Topic; Computer Simulation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epirubicin; Female; Gene Expression; Humans; Models, Biological; Necrosis; Neoplasms; Neoplastic Stem Cells; Precision Medicine; Software Design; Treatment Outcome | 2010 |
Self-assembled nanoparticles of cholesterol-conjugated carboxymethyl curdlan as a novel carrier of epirubicin.
Topics: Animals; beta-Glucans; Cell Death; Cell Proliferation; Cell Survival; Cholesterol; Drug Carriers; Epirubicin; HeLa Cells; Humans; Injections, Intravenous; Male; Mice; Microscopy, Confocal; Nanoparticles; Neoplasms; Particle Size; Rats; Rats, Wistar; Spectrophotometry, Infrared; Tissue Distribution | 2010 |
Relevance of folic acid/polymer ratio in targeted PEG-epirubicin conjugates.
Topics: Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Epirubicin; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Neoplasms; Polyethylene Glycols | 2010 |
Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cohort Studies; Doxorubicin; Echocardiography; Epirubicin; Female; Follow-Up Studies; Humans; Infant; Linear Models; Logistic Models; Male; Multivariate Analysis; Neoplasms; Netherlands; Prevalence; Prospective Studies; Risk Factors; Ventricular Dysfunction, Left | 2010 |
Epirubicin-encapsulated long-circulating thermosensitive liposome improves pharmacokinetics and antitumor therapeutic efficacy in animals.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; Epirubicin; Female; Liposomes; Mice; Neoplasm Transplantation; Neoplasms; Rats; Rats, Sprague-Dawley; Temperature; Treatment Outcome | 2011 |
Genome-wide association study of epirubicin-induced leukopenia in Japanese patients.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Case-Control Studies; Cell Cycle Proteins; Cytoskeletal Proteins; Endometrial Neoplasms; Epirubicin; Female; Genome-Wide Association Study; Humans; Japan; Leukopenia; Linkage Disequilibrium; Liver Neoplasms; Male; Neoplasms; Nerve Tissue Proteins; Polymorphism, Single Nucleotide; Prognosis; Risk Factors | 2011 |
Not exclusively tissue factor: neutrophil extracellular traps provide another link between chemotherapy and thrombosis.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; DNA; Doxorubicin; Endothelial Cells; Epirubicin; Female; Histones; Humans; Monocytes; Neoplasms; Protein C; Thrombin; Thrombomodulin; Thrombophilia; Thromboplastin; Thrombosis | 2011 |
Toxicity associated with epirubicin treatments in a large case series of dogs.
Topics: Animals; Antibiotics, Antineoplastic; Dog Diseases; Dogs; Epirubicin; Female; Fever; Gastrointestinal Diseases; Male; Neoplasms; Neutropenia; Retrospective Studies | 2012 |
[Early detection of anthracyclines cardiotoxicity by tissue Doppler echocardiography about 45 cases at Abidjan institute of cardiology].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Cardiomyopathies; Cardiotoxins; Developing Countries; Dose-Response Relationship, Drug; Doxorubicin; Echocardiography, Doppler; Epirubicin; Female; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Mitral Valve; Neoplasms; Stroke Volume; Systole; Togo; Ventricular Dysfunction, Left | 2013 |
[Short and medium term cardiotoxicity of anthracyclins: a prospective study].
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Morocco; Myocardial Contraction; Myocarditis; Neoplasms; Prospective Studies; Risk Factors; Time Factors; Ultrasonography; Ventricular Dysfunction, Left | 2012 |
Emerging topics in anaemia and cancer.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Antimicrobial Cationic Peptides; Disease Progression; Epirubicin; Erythrocytes; Erythroid Precursor Cells; Hematinics; Hepcidins; Humans; Iron; Meta-Analysis as Topic; Neoplasms; Quality of Life; Receptors, Erythropoietin | 2012 |
Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Dendritic Cells; Docetaxel; Epirubicin; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukocyte Count; Leukocytes, Mononuclear; Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2002 |
Search of anti-adriamycin antibodies in serum of cancer patients under chemotherapic treatment.
Topics: Antineoplastic Agents; DNA Adducts; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Humans; Immunoglobulin G; Male; Neoplasms | 2002 |
EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Kidney Diseases; Male; Neoplasms; Vincristine | 2002 |
Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Lineage; Combined Modality Therapy; Cyclophosphamide; Dendritic Cells; Epirubicin; Female; Flow Cytometry; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Paclitaxel; Th2 Cells | 2003 |
Maximum a posteriori Bayesian estimation of epirubicin clearance by limited sampling.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Bayes Theorem; Chromatography, High Pressure Liquid; Epirubicin; Humans; Middle Aged; Neoplasms | 2004 |
Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Atrial Natriuretic Factor; Epirubicin; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neoplasms; Predictive Value of Tests; Protein Precursors; Stroke Volume; Ventricular Function, Left | 2005 |
Cancer cell adaptation to chemotherapy.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Camptothecin; Cell Line, Tumor; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Neoplasms; Paclitaxel; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topotecan; Treatment Outcome; Up-Regulation | 2005 |
Addition of histone deacetylase inhibitors in combination therapy.
Topics: Antibiotics, Antineoplastic; Drug Therapy, Combination; Enzyme Inhibitors; Epirubicin; Histone Deacetylase Inhibitors; Humans; Neoplasms; Topoisomerase II Inhibitors; Valproic Acid | 2007 |
Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Cardiomyopathies; Caspases; Cell Line, Tumor; Creatine Kinase; Epirubicin; Heart; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Myocardium; Myocytes, Cardiac; Neoplasm Transplantation; Neoplasms; Polyethylene Glycols; Reverse Transcriptase Polymerase Chain Reaction; Troponin; Xenograft Model Antitumor Assays | 2007 |
[Current clinical status of new anticancer drugs].
Topics: Altretamine; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Etoposide; Humans; Mitoxantrone; Neoplasms | 1983 |
Distribution of 4'epi-doxorubicin in human tissues.
Topics: Antibiotics, Antineoplastic; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Humans; Neoplasms; Tissue Distribution | 1983 |
Phase II clinical evaluation of 4'-epi-doxorubicin.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Doxorubicin; Drug Evaluation; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms | 1983 |
Phase-II clinical trial of 4'-epi-doxorubicin in metastatic solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Doxorubicin; Drug Evaluation; Epirubicin; Female; Heart; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms | 1983 |
A phase II study of 4'-epi-doxorubicin plus cis-platinum in advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Evaluation; Epirubicin; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms | 1984 |
A phase-II clinical trial of 4'-epi-doxorubicin in advanced solid tumors.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Doxorubicin; Drug Evaluation; Epirubicin; Female; Heart; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Stroke Volume; Thrombocytopenia | 1984 |
[A phase I trial of 4'-epiadriamycin].
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Breast Neoplasms; Doxorubicin; Drug Evaluation; Epirubicin; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Stomach Neoplasms; Thrombocytopenia | 1984 |
Clinical evaluation of 4'-epi-doxorubicin in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Doxorubicin; Drug Evaluation; Electrocardiography; Epirubicin; Female; Heart Rate; Humans; Male; Middle Aged; Neoplasms | 1983 |
[Diagnosis of cancer using lymphocyte electrophoresis (2)].
Topics: Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Electrophoresis; Epirubicin; Female; Humans; Lymphocytes; Male; Membrane Potentials; Middle Aged; Neoplasms; Rectal Neoplasms; Stomach Neoplasms | 1984 |
[A phase I study of 4'-epi-adriamycin, a new anthracycline anticancer agent].
Topics: Anorexia; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Epirubicin; Humans; Leukopenia; Nausea; Neoplasms | 1984 |
Preliminary clinical experience with 4-epidoxorubicin in advanced human neoplasia.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Blood Cell Count; Doxorubicin; Drug Evaluation; Electrocardiography; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasms | 1980 |
Toxic and therapeutic activity of 4'-epi-doxorubicin.
Topics: Adolescent; Adult; Aged; Alopecia; Arrhythmias, Cardiac; Bone Marrow Diseases; Doxorubicin; Drug Evaluation; Epirubicin; Female; Heart; Humans; Male; Middle Aged; Neoplasms; Stereoisomerism; Stomatitis; Vomiting | 1982 |
Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases.
Topics: Chromatography, High Pressure Liquid; Doxorubicin; Epirubicin; Half-Life; Humans; Kidney; Kinetics; Liver Neoplasms; Neoplasms; Time Factors | 1982 |
Phase II study of 4'epi-doxorubicin.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Drug Evaluation; Epirubicin; Female; Heart; Humans; Male; Melanoma; Middle Aged; Neoplasms; Sarcoma | 1982 |
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Bone Marrow Cells; Carboplatin; Carmustine; Cell Adhesion Molecules; Cell Movement; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Epirubicin; Etoposide; Female; Fluorouracil; Gene Expression; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; L-Selectin; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Neutrophils; Platelet Count; Podophyllotoxin; Receptors, Very Late Antigen; Thiotepa | 1995 |
[Autologous stem cell harvesting after high dosage chemo- and/or growth factor therapy].
Topics: Adult; Blood Cell Count; Combined Modality Therapy; Cyclophosphamide; Cytapheresis; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Neoplasms; Remission Induction; Survival Rate; Transplantation, Autologous | 1995 |
Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy.
Topics: 3-Iodobenzylguanidine; Adrenergic Fibers; Adult; Doxorubicin; Epirubicin; Female; Heart; Humans; Iodine Radioisotopes; Iodobenzenes; Male; Middle Aged; Myocardium; Neoplasms; Radionuclide Imaging; Stroke Volume | 1995 |
Epirubicin cardiotoxicity: a study comparing low- with high-dose-intensity weekly schedules.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Heart Failure; Humans; Incidence; Male; Middle Aged; Neoplasms; Stroke Volume | 1996 |
Preclinical experiences with magnetic drug targeting: tolerance and efficacy.
Topics: Animals; Antibiotics, Antineoplastic; Drug Delivery Systems; Embolization, Therapeutic; Epirubicin; Magnetics; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Rats; Rats, Sprague-Dawley | 1996 |
Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Blood Transfusion, Autologous; Bone Marrow; Carmustine; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Synergism; Epirubicin; Etoposide; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Injections, Subcutaneous; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Recombinant Proteins | 1996 |
Serum troponin T levels in adults undergoing anthracycline therapy.
Topics: Adult; Antibiotics, Antineoplastic; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Epirubicin; Heart Diseases; Humans; Middle Aged; Neoplasms; Time Factors; Troponin | 1997 |
Circulating immature cell counts on the harvest day predict the yields of CD34+ cells collected after granulocyte colony-stimulating factor plus chemotherapy-induced mobilization of peripheral blood stem cell.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Cytarabine; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukocyte Count; Male; Middle Aged; Neoplasms | 1997 |
Epirubicin-induced oxidative DNA damage and evidence for its repair in lymphocytes of cancer patients who are undergoing chemotherapy.
Topics: Adult; Antibiotics, Antineoplastic; Chromatin; DNA Damage; DNA Repair; DNA, Neoplasm; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasms | 1997 |
Pilot study of multiple chemotherapy resistance modulators plus epirubicin in the treatment of resistant malignancies.
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antifungal Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Antitrichomonal Agents; Cyclosporine; Dipyridamole; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Immunosuppressive Agents; Ketoconazole; Male; Metronidazole; Middle Aged; Neoplasms; Pilot Projects; Tamoxifen; Vasodilator Agents | 1997 |
Does the multidrug-resistance modulator cyclosporin A increase the cardiotoxicity of high-dose anthracycline chemotherapy?
Topics: Adolescent; Adult; Aged; Analysis of Variance; Animals; Antibiotics, Antineoplastic; Cyclosporine; Doxorubicin; Drug Resistance, Multiple; Drug Synergism; Epirubicin; Female; Heart; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Ventricular Function, Left | 1997 |
Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Epirubicin; Evidence-Based Medicine; Female; Heart; Heart Failure; Humans; Neoplasms; Odds Ratio; Randomized Controlled Trials as Topic; Razoxane; Time Factors; Treatment Outcome | 1999 |
Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colony-Forming Units Assay; Cyclophosphamide; Drug Synergism; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Immunophenotyping; Leukapheresis; Leukocyte Count; Male; Neoplasms | 1999 |
Evaluation of drug interactions in the established FEC regimen in primary cultures of tumour cells from patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Drug Synergism; Epirubicin; Fluorouracil; Humans; Neoplasms; Tumor Cells, Cultured | 2000 |
Quality of life in cancer patients treated by chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Colorectal Neoplasms; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Neoplasms; Quality of Life; Stomach Neoplasms; Surveys and Questionnaires | 2000 |
Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Interactions; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Radiation-Protective Agents; Radiation-Sensitizing Agents | 2001 |
Chemotherapy of solid tumors in private practice in Malaysia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Fluorouracil; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Malaysia; Methotrexate; Mitomycin; Nasopharyngeal Neoplasms; Neoplasms; Private Practice | 1992 |
[Nutritional support for cancer bearing patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Home Nursing; Humans; Infusion Pumps, Implantable; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neoplasms; Parenteral Nutrition, Home; Quality of Life; Stomach Neoplasms | 1991 |
Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Stability; Epirubicin; Etoposide; Feasibility Studies; Female; Humans; Ifosfamide; Infusion Pumps, Implantable; Infusions, Intravenous; Male; Mesna; Middle Aged; Mitoxantrone; Neoplasms | 1991 |
Continuous infusion of chemotherapy on an outpatient basis via a totally implanted venous access port.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Evaluation; Epirubicin; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Infusions, Intravenous; Male; Middle Aged; Mitoxantrone; Neoplasms; Self Administration | 1991 |
Disposition of epirubicin and metabolites with repeated courses to cancer patients.
Topics: Adult; Aged; Epirubicin; Female; Glucuronates; Humans; Male; Middle Aged; Neoplasms | 1991 |
Intracellular magnesium concentrations and acute anthracycline-induced cardiotoxicity.
Topics: Doxorubicin; Electrolytes; Epirubicin; Erythrocytes; Female; Heart; Humans; Magnesium; Male; Middle Aged; Neoplasms | 1991 |
High-dose epirubicin for untreated patients with advanced tumours: a phase I study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms | 1990 |
Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug.
Topics: Epirubicin; Glucuronates; Humans; Neoplasms; Retrospective Studies | 1990 |
Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
Topics: Biotransformation; Chromatography, High Pressure Liquid; Drug Administration Schedule; Epirubicin; Female; Humans; Injections, Intravenous; Leukocyte Count; Male; Middle Aged; Neoplasms; Platelet Count | 1990 |
[Pharmacokinetics of epirubicin in alcoholic patients].
Topics: Alcoholism; Epirubicin; Humans; Neoplasms | 1989 |
[Advances in intercalating drugs].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Humans; Intercalating Agents; Mitoxantrone; Neoplasms | 1989 |
Acute effects of various chemotherapeutic combinations on hypophyseal and pineal hormone secretions in cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; beta-Endorphin; Cisplatin; Cyclophosphamide; Doxorubicin; Endorphins; Epirubicin; Female; Fluorouracil; Humans; Hydrocortisone; Male; Melatonin; Methotrexate; Neoplasms; Pineal Gland; Pituitary Gland, Anterior; Pituitary Hormones, Anterior; Secretory Rate; Vincristine | 1987 |
The role of pharmacokinetics in the clinical treatment of metastases.
Topics: Antineoplastic Agents; Doxorubicin; Epirubicin; Humans; Liver Neoplasms; Medroxyprogesterone; Medroxyprogesterone Acetate; Neoplasm Metastasis; Neoplasms; Tamoxifen | 1988 |
Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.
Topics: Chromatography, High Pressure Liquid; Doxorubicin; Epirubicin; Fluorometry; Humans; Metabolic Clearance Rate; Neoplasms | 1988 |
[Clinical study of acute cardiotoxicity of anti-cancer agents-- analysis using Holter ECG monitoring].
Topics: Adult; Aged; Doxorubicin; Electrocardiography; Epirubicin; Female; Heart; Heart Rate; Humans; Male; Middle Aged; Mitoxantrone; Monitoring, Physiologic; Neoplasms | 1988 |
[Pharmacokinetics of epirubicin in cancer patients].
Topics: Chromatography, High Pressure Liquid; Doxorubicin; Epirubicin; Humans; Infusions, Parenteral; Kinetics; Neoplasms | 1986 |
Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients.
Topics: Bile; Biological Availability; Chromatography, Liquid; Doxorubicin; Epirubicin; Humans; Liver Diseases; Middle Aged; Neoplasms | 1986 |
An attempt at applying epiadriamycin to the patients for whom doxorubicin is cardiologically contraindicated.
Topics: Adult; Aged; Doxorubicin; Epirubicin; Female; Heart; Humans; Male; Middle Aged; Neoplasms; Stereoisomerism | 1986 |
A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin.
Topics: Adult; Aged; Antineoplastic Agents; Doxorubicin; Drug Evaluation; Epirubicin; Female; Humans; Infusion Pumps; Kinetics; Male; Middle Aged; Neoplasms; Time Factors | 1987 |
Evaluation of a totally implanted venous access port and portable pump in a continuous chemotherapy infusion schedule on an outpatient basis.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Epirubicin; Female; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Mitoxantrone; Neoplasms; Self Administration | 1987 |
[4'-epidoxorubicin].
Topics: Antibiotics, Antineoplastic; Doxorubicin; Epirubicin; Humans; Neoplasms | 1985 |
Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone.
Topics: Adolescent; Adult; Aged; Angiocardiography; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents; Coronary Vessels; Doxorubicin; Epirubicin; Female; Heart; Heart Ventricles; Humans; Middle Aged; Mitoxantrone; Neoplasms; Radionuclide Imaging; Stroke Volume | 1985 |
Epirubicin plasma and blood pharmacokinetics after single i.v. bolus in advanced cancer patients.
Topics: Bile; Doxorubicin; Epirubicin; Half-Life; Humans; Kidney Diseases; Kinetics; Liver Neoplasms; Mathematics; Neoplasms | 1985 |